Technical Analysis for CSTL - Castle Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
41.54 | -0.62% | -0.26 |
CSTL closed down 0.62 percent on Monday, August 10, 2020, on 83 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Aug 10
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Historical CSTL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| 20 DMA Support | Bullish | -0.62% | |
| NR7 | Range Contraction | -0.62% | |
| Inside Day | Range Contraction | -0.62% | |
| Bearish Engulfing | Bearish | -0.26% | |
| 20 DMA Support | Bullish | -0.26% | |
| MACD Bullish Signal Line Cross | Bullish | -0.26% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/10/2020
- Sector: Healthcare
- Industry: Diagnostics & Research
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Medicine Health Cancer Clinical Medicine Medical Tests Gene Expression Melanoma Metastasis
Medicine Health Cancer Clinical Medicine Medical Tests Gene Expression Melanoma Metastasis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 45.62 |
| 52 Week Low | 15.26 |
| Average Volume | 213,549 |
| 200-Day Moving Average | 32.09 |
| 50-Day Moving Average | 39.97 |
| 20-Day Moving Average | 41.09 |
| 10-Day Moving Average | 40.53 |
| Average True Range | 2.04 |
| ADX | 16.41 |
| +DI | 16.90 |
| -DI | 21.28 |
| Chandelier Exit (Long, 3 ATRs ) | 39.51 |
| Chandelier Exit (Short, 3 ATRs ) | 42.25 |
| Upper Bollinger Band | 44.45 |
| Lower Bollinger Band | 37.74 |
| Percent B (%b) | 0.57 |
| BandWidth | 16.33 |
| MACD Line | 0.38 |
| MACD Signal Line | 0.30 |
| MACD Histogram | 0.0775 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 43.39 | ||||
| Resistance 3 (R3) | 43.45 | 42.88 | 43.08 | ||
| Resistance 2 (R2) | 42.88 | 42.41 | 42.85 | 42.98 | |
| Resistance 1 (R1) | 42.21 | 42.12 | 41.93 | 42.16 | 42.88 |
| Pivot Point | 41.65 | 41.65 | 41.50 | 41.62 | 41.65 |
| Support 1 (S1) | 40.98 | 41.17 | 40.69 | 40.92 | 40.20 |
| Support 2 (S2) | 40.41 | 40.88 | 40.38 | 40.10 | |
| Support 3 (S3) | 39.74 | 40.41 | 40.00 | ||
| Support 4 (S4) | 39.69 |
